United Greeneries Receives Dealer’s License to Allow for Imports and Exports of Cannabis Products and Establishing of Product Development Platform
Harvest One Cannabis Inc. (TSXV: HVT) (“Harvest One” or the “Company“) is pleased to advise that its wholly owned subsidiary, United Greeneries (“United Greeneries” or “UG“), has received a Dealer’s License pursuant to the Controlled Drugs and Substances Act under Health Canada.
The license now allows UG to import narcotics into Canada, including its signature Gelpell Microgel CBD capsules that are produced in Switzerland and that are already sold as a nutritional supplement in the European Union and as a prescription drug in Australia.
The Dealer’s License further allows the Company to export its medical cannabis products to other markets with favourable medical marijuana regulations, including Germany.
With this license, the Company will also further engage in research and development of cannabis infused products and is preparing a state-of-the art product development centre at its Duncan facility in British Columbia, planning to soon offer several value-add services to the industry, including a full quality control laboratory and co-packaging.
“Securing our Dealer’s License is a significant milestone for United Greeneries and Harvest One. This is an important step in supplying our Satipharm products to Canadian consumers and also allows us to expedite the development of Dream Water’s CBD infused product line,” said Andreas Gedeon, CEO of Harvest One. “We will be expanding our global presence and leveraging Satipharm’s supply agreements to bring our products to international markets.”
About Harvest One Cannabis Inc. (TSXV: HVT)
Harvest One is a global cannabis company focused on delivering high quality, innovative cannabis products and technology to regulated markets around the world. Shareholders have significant exposure to the entire cannabis value chain through three wholly owned operating subsidiaries: Horticultural arm and Canadian Licensed Producer United Greeneries Ltd., medical and pharmaceutical arm Satipharm AG in Switzerland and Dream Water Global, the Group’s consumer goods division.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The forward-looking information contained in this press release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.